vetklinfo
vetklinfo · EMA/CVMP · 13 November 2026

EMA/CVMP: Five positive opinions in November 2026

The CVMP recommended five veterinary medicines, including Scovella, Laverdia and Streptoporc. European Commission decisions are still pending.

Overview

At its meeting of 3–5 November 2026, the CVMP adopted five positive opinions on applications for centralised marketing authorisations. EMA published the meeting highlights on 6 November 2026.

The five medicines

Scovella (velagliflozin) is intended to reduce hyperinsulinaemia and the associated risk of laminitis in horses with Equine Metabolic Syndrome not adequately responding to husbandry and exercise changes. Credelio Quattro (lotilaner, moxidectin, pyrantel and praziquantel) is intended for dogs requiring simultaneous treatment against ectoparasites, cestodes and nematodes. Laverdia (verdinexor) is intended to increase time to progression in dogs with stage II–IV lymphoma where home treatment is indicated. Streptoporc is intended for passive immunisation of piglets through vaccination of pregnant sows and gilts against specified Streptococcus suis infections of IdeSsuis genotype 1.1. Nobivac PLUS DHPPi / Leptos is a combination vaccine for dogs from six weeks of age against several viral and bacterial pathogens.

Limited-market framework

EMA identifies Scovella as the first veterinary medicinal product recommended under the limited-market framework since Regulation (EU) 2019/6 took effect. Tailored dossier requirements remain subject to eligibility criteria and a favourable benefit–risk assessment.

Regulatory status

A positive CVMP opinion is a scientific recommendation and is not equivalent to a European Commission marketing authorisation. Final decisions and product information must be checked separately.

Practical implications

Developers and marketing authorisation holders should monitor Commission decisions, EPARs and product information. Eligibility for the limited-market pathway requires a product-specific assessment.

Official primary source

EMA: CVMP Meeting Highlights, 3–5 November 2026 (published 6 November 2026)

As of 13 November 2026. Scientific interpretation; official source documents take precedence.

← Back to Regulatory Updates